These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22155366)

  • 1. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
    Amura CR; Brodsky KS; Groff R; Gattone VH; Voelkel NF; Doctor RB
    Am J Physiol Cell Physiol; 2007 Jul; 293(1):C419-28. PubMed ID: 17475663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
    Lee SO; Masyuk T; Splinter P; Banales JM; Masyuk A; Stroope A; Larusso N
    J Clin Invest; 2008 Nov; 118(11):3714-24. PubMed ID: 18949056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
    Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
    Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice.
    Doctor RB; Serkova NJ; Hasebroock KM; Zafar I; Edelstein CL
    Nephrol Dial Transplant; 2010 Nov; 25(11):3496-504. PubMed ID: 20388629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
    Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
    PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
    Masyuk TV; Lee SO; Radtke BN; Stroope AJ; Huang B; Banales JM; Masyuk AI; Splinter PL; Gradilone SA; Gajdos GB; LaRusso NF
    Am J Pathol; 2014 Jan; 184(1):110-21. PubMed ID: 24211536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
    Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
    Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The zebrafish as a model to study polycystic liver disease.
    Tietz Bogert PS; Huang BQ; Gradilone SA; Masyuk TV; Moulder GL; Ekker SC; Larusso NF
    Zebrafish; 2013 Jun; 10(2):211-7. PubMed ID: 23668934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
    Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
    JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.
    Wang X; Ye H; Ward CJ; Chu JY; Masyuk TV; Larusso NF; Harris PC; Chow BK; Torres VE
    Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1089-98. PubMed ID: 22811488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
    Wang X; Harris PC; Somlo S; Batlle D; Torres VE
    Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
    J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
    Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
    United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.
    Zhang M; Srichai MB; Zhao M; Chen J; Davis LS; Wu G; Breyer MD; Hao CM
    Int J Med Sci; 2019; 16(1):180-188. PubMed ID: 30662341
    [No Abstract]   [Full Text] [Related]  

  • 18. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
    Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
    Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepato-renal pathology in pkd2ws25/- mice, an animal model of autosomal dominant polycystic kidney disease.
    Stroope A; Radtke B; Huang B; Masyuk T; Torres V; Ritman E; LaRusso N
    Am J Pathol; 2010 Mar; 176(3):1282-91. PubMed ID: 20093497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for microRNA in cystic liver and kidney diseases.
    Chu AS; Friedman JR
    J Clin Invest; 2008 Nov; 118(11):3585-7. PubMed ID: 18949060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.